Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EBIO

Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis

Eleven Biotherapeutics logo

About Eleven Biotherapeutics Stock (NASDAQ:EBIO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
15.58 million shs
Average Volume
2.86 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Receive EBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eleven Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

EBIO Stock News Headlines

Atara Biotherapeutics Inc.
Flagship Ventures Fund IV-Rx, L.P.'s Net Worth
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Headlines

EBIO Stock Analysis - Frequently Asked Questions

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) posted its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), SELLAS Life Sciences Group (SLS), Sesen Bio (SESN), TransEnterix (TRXDW) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
5/15/2018
Today
5/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EBIO
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:EBIO) was last updated on 5/13/2025 by MarketBeat.com Staff
From Our Partners